- Home
- Companies
- luxembourg
- antigen targeted
Show results for
Refine by
Antigen Targeted Suppliers Serving Luxembourg
40 companies found
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can't solve. So we added antibody phage display ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many ...
based inOxford, UNITED KINGDOM
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth ...
Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
DBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate ...
based inShirley, NEW YORK (USA)
CD BioSciences is a leading customer-focused biotechnology company founded in New York. Virus-like particles (VLPs) constructed on plant-based platforms can be produced on a large scale as plants can be grown cheaply and efficiently without the need ...
As is a leading global custom service provider, CD BioSciences dedicated to delivering highly customized and integrated solutions with the best quality to advance our customers' projects. CD BioSciences has a sophisticated VLPlantTM platform and ...
based inNew Delhi, INDIA
Takara Bio companies provide kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, DSS Takara Bio India Private Ltd. is part of a company that holds ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inCambridge, UNITED KINGDOM
Based in Cambridge, one of Europe's largest bioscience hubs, Biorbyt has a simple yet challenging mission: to provide the best service to the global scientific community. We achieve this by collaborating with the world’s finest researchers and ...
Plasma cells are specialised B lymphocytes that secrete antibodies (glycoproteins) in response to infection by antigens (toxins or foreign substances). Antibodies, also known as immunoglobulins (Ig), usually have a high affinity to a specific ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inSan Diego, CALIFORNIA (USA)
Founded originally in Vancouver, British Columbia in 2006 by three enthusiastic entrepreneurs passionate about providing the best biological reagents worldwide, MyBiosource, Inc. was incorporated as a company with big visions. Since 2007, we have ...
Product Gene Name: ADP elisa kit. Research Use Only: For Research Use Only. Not for use in diagnostic ...
based inShirley, NEW YORK (USA)
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many ...
based inRedcar, UNITED KINGDOM
Absolute Antibody was founded in 2012 with a vision to make engineered recombinant antibodies accessible to all, and we remain the only company 100% focused on recombinant antibody technology. Though recombinant antibodies are standard in the ...
Binding multiple epitopes with a single antibody offers several benefits. For example, one specificity may target individual molecules while another could recruit effector cells or deliver a drug to the target. Other options include dual-target ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
The dual target antibody platform technology of PharmAbcine is based on the fully human antibody candidates selected from HuPhage biopanning process. Depending on antigen presentation patterns on ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous gamma delta T cell receptor (TCR), and combines it with chimeric antigen receptors. This involves ...
based inMons, BELGIUM
D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris). The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is ...
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while ...